deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT06419582

BHV-7000 Acute Treatment of Bipolar Mania

A Phase 2/3, Multicenter, Inpatient, Placebo-Controlled, Double-blind Trial of BHV-7000 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

Sponsor: Biohaven Therapeutics Ltd.

Interventions BHV-7000 Placebo
Updated 9 times since 2024 Last updated: Dec 13, 2025 Started: May 28, 2024 Primary completion: Jan 15, 2025 Completion: Jan 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06419582, this PHASE2/PHASE3 trial focuses on Bipolar Disorder and remains completed. Sponsored by Biohaven Therapeutics Ltd., it has been updated 9 times since 2024, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshotRecruiting~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshotRecruiting~Jan 2025 – ~Apr 2025 · 3 months · monthly snapshotActive Not Recruiting~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshotCompleted~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshotCompleted~Jan 2026 – present · 6 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2025 — Jan 2026 [monthly]

    Completed PHASE2/PHASE3

  3. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

    Status: Active Not RecruitingCompleted

  4. Jan 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2/PHASE3

    Status: RecruitingActive Not Recruiting

  5. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE2/PHASE3

Show 4 earlier versions
  1. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2/PHASE3

  2. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2/PHASE3

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3PHASE2/PHASE3

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

May 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biohaven Therapeutics Ltd.
Data source: Biohaven Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .